This volume presents up-to-date, comprehensive and high quality reviews of the psychopharmacological evidence-base for each of the major psychiatric disorders, written by expert psychopharmacologists from around the world. Building on the success of the first edition, the volume summarizes the wealth of new developments in the field and sets them within the context of day-to-day clinical practice. All chapters have been fully updated and new contributions on personality disorders and substance dependence added. Each chapter provides information about optimal first line pharmacological interventions, maintenance pharmacotherapy and the management of treatment-refractory patients. The content is organized according to the DSM-V listing of psychiatric disorders, and covers all major conditions including schizophrenia, mood disorders, anxiety disorders, eating disorders and Alzheimer's disorder. These issues lie at the heart of clinical psychopharmacology, making this book invaluable to all practising and trainee clinicians, in a mental health setting or a less specialised environment.
This volume presents up-to-date, comprehensive and high quality reviews of the psychopharmacological evidence-base for each of the major psychiatric disorders, written by expert psychopharmacologists from around the world. Building on the success of the first edition, the volume summarizes the wealth of new developments in the field and sets them within the context of day-to-day clinical practice. All chapters have been fully updated and new contributions on personality disorders and substance dependence added. Each chapter provides information about optimal first line pharmacological interventions, maintenance pharmacotherapy and the management of treatment-refractory patients. The content is organized according to the DSM-V listing of psychiatric disorders, and covers all major conditions including schizophrenia, mood disorders, anxiety disorders, eating disorders and Alzheimer's disorder. These issues lie at the heart of clinical psychopharmacology, making this book invaluable to all practising and trainee clinicians, in a mental health setting or a less specialised environment.
Inhaltsverzeichnis
Preface; Foreword; 1. Evidence-based pharmacotherapy of attention deficit hyperactivity disorder Brigitte S. Vaughan, John S. March and Christopher J. Kratochvil; 2. Evidence-based pharmacotherapy of schizophrenia Stefan Leucht, Stephan Heres, Werner Kissling and John M. Davis; 3. Evidence-based pharmacotherapy of bipolar disorder Matthew J. Taylor and John R. Geddes; 4. Evidence-based pharmacotherapy of major depressive disorder Jamie M. Dupuy, Michael J. Ostacher, Jeffrey Huffman, Roy H. Perlis and Andrew A. Nierenberg; 5. Evidence-based pharmacotherapy of panic disorder Neeltje M. Batelaan, Anton J. L. M. Van Balkom and Dan J. Stein; 6. Evidence-based pharmacotherapy of social anxiety disorder Carlos Blanco, Laura B. Bragdon, Franklin R. Schneier and Michael R. Liebowitz; 7. Evidence-based pharmacotherapy of generalised anxiety disorder David S. Baldwin, Sarah Waldman and Christer Allgulander; 8. Evidence-based pharmacotherapy of obsessive-compulsive disorder Naomi A. Fineberg, Angus Brown and Ilenia Pampaloni; 9. Evidence-based pharmacotherapy of posttraumatic stress disorder Jonathan C. Ipser and Dan J. Stein; 10. Evidence-based pharmacotherapy of eating disorders Martine F. Flament, Hany Bissada and Wendy Spettigue; 11. Evidence-based pharmacotherapy of nicotine and alcohol dependence Wim van den Brink; 12. Evidence-based pharmacotherapy of illicit substance use disorders Wim van den Brink; 13. Evidence-based pharmacotherapy of Alzheimer's disease Darren Cotterell and Martin Brown; 14. Evidence-based pharmacotherapy of personality disorders Luis H. Ripoll, Joseph Triebwasser and Larry J. Siever; Index.
